Versican Plus Pi/L4R

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

canine parainfluenza virus, leptospira and rabies virus.

Available from:

Zoetis Belgium S.A.

ATC code:

QI07AJ

INN (International Name):

canine parainfluenza virus, leptospira and rabies virus

Therapeutic group:

Кучета

Therapeutic area:

Имуномодулатори за псовые, жив и инактивированных вирусни и бактериални ваксини

Therapeutic indications:

Активна имунизация на кучета от шест-седмично възраст, за предотвратяване на клиничните симптоми и намаляване на вирусната екскреция причината за кучешки, parainfluenza virus, за да се предотврати клиничните признаци, както и инфекции на пикочните екскреция причина Лептоспир развлечения Братислава, тянитолкая, grippotyphosa и icterohaemorrhagiae и предотвратяване на смъртността, клиничните признаци и причини за инфекция на вируса на бяс.

Product summary:

Revision: 5

Authorization status:

упълномощен

Authorization date:

2014-07-30

Patient Information leaflet

                                17
B. ЛИСТОВКА
18
ЛИСТОВКА:
VERSICAN PLUS PI/L4R ЛИОФИЛИЗАТ И СУСПЕНЗИЯ ЗА
ИНЖЕКЦИОННА СУСПЕНЗИЯ ЗА КУЧЕТА
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА УПОТРЕБА
И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
Притежател на лиценза за употреба:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
БЕЛГИЯ
Производител, отговорен за
освобождаване на партидата:
Bioveta, a.s.,
Komenského 212,
683 23 Ivanovice na Hané,
РЕПУБЛИКА ЧЕХИЯ
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Versican Plus Pi/L4R лиофилизат и суспензия за
инжекционна
суспензия за кучета
3.
СЪДЪРЖАНИЕ НА АКТИВНИТЕ СУБСТАНЦИИ И
ЕКСЦИПИЕНТИТЕ
Всяка доза от 1 ml съдържа:
АКТИВНИ СУБСТАНЦИИ:
ЛИОФИЛИЗАТ (ЖИВ АТЕНЮИРАН):
MINIMUM
MAXIMUM
_Canine parainfluenza Type 2 virus_
, strain CPiV-2 Bio 15
10
3.1
TCID
50
*
10
5.1
TCID
50
*
СУСПЕНЗИЯ (ИНАКТИВИРАНA)
:
_Leptospira interrogans_
serogroup Icterohaemorrhagiae
serovar Icterohaemorrhagiae strain MSLB 1089
ALR** titre ≥ 1:51
_Leptospira interrogans _
serogroup Canicola
_ _
serovar Canicola, strain MSLB 1090
ALR** titre ≥ 1:51
_Leptospira kirschneri _
serogroup Grippotyphosa
_ _
serovar Grippotyphosa
_,_
strain MSLB 1091
ALR** titre ≥ 1:40
_Leptospira interrogans _
serogroup Australis
_ _
serovar Bratislava
_,_
strain MSLB 1088
ALR** titre ≥ 1:51
Rabies virus, strain SAD Vnukovo-32
≥ 2.0 IU***
АДЖУВАНТ:
Aluminium hydroxide
1.8–2.2 mg.
*
Тъканна културално инфекциозна
доза 50%.
**
Антитела микро аглутинация-литична
реакция.
***
Международни едини
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Versican Plus Pi/L4R, лиофилизат и суспензия за
инжекционна
суспензия за кучета
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка доза от 1 ml съдържа:
АКТИВНИ СУБСТАНЦИИ:
ЛИОФИЛИЗАТ (ЖИВ АТЕНЮИРАН):_ _
MINIMUM
MAXIMUM
_ _
_Canine parainfluenza Type 2 virus_
, strain CPiV-2 Bio 15
10
3.1
TCID
50
*
10
5.1
TCID
50
*
СУСПЕНЗИЯ (ИНАКТИВИРАНA)
:
_Leptospira interrogans_
serogroup Icterohaemorrhagiae
serovar Icterohaemorrhagiae strain MSLB 1089
ALR** titre ≥ 1:51
_Leptospira interrogans_
serogroup Canicola
_ _
serovar Canicola, strain MSLB 1090
ALR** titre ≥ 1:51
_Leptospira kirschneri _
serogroup Grippotyphosa
_ _
serovar Grippotyphosa
_,_
strain MSLB 1091
ALR** titre ≥ 1:40
_Leptospira interrogans _
serogroup Australis
_ _
serovar Bratislava
_,_
strain MSLB 1088
ALR** titre ≥ 1:51
Rabies virus, strain SAD Vnukovo-32
≥ 2.0 IU***
*
Тъканна културално инфекциозна
доза 50%.
**
Антитела микро аглутинация-литична
реакция.
***
Международни единици.
АДЖУВАНТ:
Aluminium hydroxide
1.8–2.2 mg.
ЕКСЦИПИЕНТИ:
За пълния списък на ексципиентите, виж
т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Лиофилизат и суспензия за инжекционна
суспензия.
Външният вид на компонентите е както
следва:
Лиофилизат:
бяло оцветено, шуплесто съдържимо.
Суспензия: розово оцветенa с фин
седимент.
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Кучета.
4.2
Т
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 17-05-2019
Public Assessment Report Public Assessment Report Spanish 20-10-2014
Patient Information leaflet Patient Information leaflet Czech 17-05-2019
Public Assessment Report Public Assessment Report Czech 20-10-2014
Patient Information leaflet Patient Information leaflet Danish 17-05-2019
Public Assessment Report Public Assessment Report Danish 20-10-2014
Patient Information leaflet Patient Information leaflet German 17-05-2019
Public Assessment Report Public Assessment Report German 20-10-2014
Patient Information leaflet Patient Information leaflet Estonian 17-05-2019
Public Assessment Report Public Assessment Report Estonian 20-10-2014
Patient Information leaflet Patient Information leaflet Greek 17-05-2019
Public Assessment Report Public Assessment Report Greek 20-10-2014
Patient Information leaflet Patient Information leaflet English 17-05-2019
Public Assessment Report Public Assessment Report English 20-10-2014
Patient Information leaflet Patient Information leaflet French 17-05-2019
Public Assessment Report Public Assessment Report French 20-10-2014
Patient Information leaflet Patient Information leaflet Italian 17-05-2019
Public Assessment Report Public Assessment Report Italian 20-10-2014
Patient Information leaflet Patient Information leaflet Latvian 17-05-2019
Public Assessment Report Public Assessment Report Latvian 20-10-2014
Patient Information leaflet Patient Information leaflet Lithuanian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 17-05-2019
Public Assessment Report Public Assessment Report Lithuanian 20-10-2014
Patient Information leaflet Patient Information leaflet Hungarian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 17-05-2019
Public Assessment Report Public Assessment Report Hungarian 20-10-2014
Patient Information leaflet Patient Information leaflet Maltese 17-05-2019
Public Assessment Report Public Assessment Report Maltese 20-10-2014
Patient Information leaflet Patient Information leaflet Dutch 17-05-2019
Public Assessment Report Public Assessment Report Dutch 20-10-2014
Patient Information leaflet Patient Information leaflet Polish 17-05-2019
Public Assessment Report Public Assessment Report Polish 20-10-2014
Patient Information leaflet Patient Information leaflet Portuguese 17-05-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 17-05-2019
Public Assessment Report Public Assessment Report Portuguese 20-10-2014
Patient Information leaflet Patient Information leaflet Romanian 17-05-2019
Public Assessment Report Public Assessment Report Romanian 20-10-2014
Patient Information leaflet Patient Information leaflet Slovak 17-05-2019
Public Assessment Report Public Assessment Report Slovak 20-10-2014
Patient Information leaflet Patient Information leaflet Slovenian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Slovenian 17-05-2019
Public Assessment Report Public Assessment Report Slovenian 20-10-2014
Patient Information leaflet Patient Information leaflet Finnish 17-05-2019
Public Assessment Report Public Assessment Report Finnish 20-10-2014
Patient Information leaflet Patient Information leaflet Swedish 17-05-2019
Public Assessment Report Public Assessment Report Swedish 20-10-2014
Patient Information leaflet Patient Information leaflet Norwegian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 17-05-2019
Patient Information leaflet Patient Information leaflet Icelandic 17-05-2019
Summary of Product characteristics Summary of Product characteristics Icelandic 17-05-2019
Patient Information leaflet Patient Information leaflet Croatian 17-05-2019
Public Assessment Report Public Assessment Report Croatian 20-10-2014